Aria CV

Aria CV is a medical device company developing a novel implantable system to treat pulmonary hypertension, a serious lung-related cardiovascular disease. Their device aims to restore healthy pulmonary artery function, reducing heart workload and improving blood flow and quality of life.

Investment Details

Portfolia Fund

Funding Round

Series B

Milestones

Funded in 2020, 2022, and 2023

About the Founder

Dr. John Scandurra

Dr. Scandurra is a co-founder and Chief Scientific Officer at Aria CV, Inc., where he leads the development of Aria’s novel therapy for pulmonary hypertension and right heart failure. He is responsible for managing the company’s Scientific Advisory Board, fostering collaboration within the pulmonary hypertension physician community, and driving therapy development efforts. Before founding Aria, Dr. Scandurra was a Senior Fellow at the University of Minnesota’s Medical Devices Center, where he and his team invented Aria’s core technology. His multidisciplinary expertise spans medicine and engineering, bringing a unique perspective to medical innovation. Dr. Scandurra holds a Doctor of Veterinary Medicine (DVM) degree with post-doctoral clinical training in veterinary cardiology, as well as Bachelor’s and Master’s degrees in Mechanical Engineering.

Real Investors. Real Outcomes.

“I have learned so much about leadership, financial well-being, and the power of connection from the amazing community of women at Portfolia.”

Peggy Northrop

CEO of Watermark and Former Editor-in-Chief of More Magazine, Connecticut

“I love the concept of being able to invest and collaborate with others, mitigating my own risk by investing in a portfolio. It lets me see more deals in the pipeline.”

Chantell Preston

Healthcare Executive, Houston, TX

“I joined because I was excited that the model was more like a mutual fund and offered exposure to so many companies and opportunities to further learning.”

Namrita Kapur

Fellow, Yale School of Management, Boston, MA